Patents by Inventor Mark Andrew Seefeld

Mark Andrew Seefeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic Amides as Kinase Inhibitors
    Publication number: 20230192676
    Abstract: Disclosed are compounds having the formula (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: December 27, 2018
    Publication date: June 22, 2023
    Inventors: Ryan Michael Fox, Philip Anthony Harris, Joerg Holenz, Mark Andrew Seefeld, Ding Zhou
  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    Publication number: 20190048016
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Application
    Filed: November 19, 2015
    Publication date: February 14, 2019
    Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    Publication number: 20180319810
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Application
    Filed: November 19, 2015
    Publication date: November 8, 2018
    Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michaael FOX, William Henry MILLER, Mark Andrew SEEFELD
  • Substituted bridged urea analogs as sirtuin modulators
    Patent number: 10072011
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 11, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: James Lamond Ellis, Karen Anderson Evans, Ryan Michael Fox, William Henry Miller, Mark Andrew Seefeld
  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    Publication number: 20170362234
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Application
    Filed: November 19, 2015
    Publication date: December 21, 2017
    Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    Publication number: 20170355705
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Application
    Filed: November 19, 2015
    Publication date: December 14, 2017
    Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160122342
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Inventors: David T. FOSBENNER, Bryan W. KING, Steven David KNIGHT, Louis Vincent LaFRANCE, III, Mei LI, Kenneth C. McNULTY, Stuart Paul ROMERIL, Mark Andrew SEEFELD
  • Inhibitors of Akt activity
    Patent number: 8592475
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: November 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Meagan B. Rouse, Mark Andrew Seefeld
  • Inhibitors of Akt activity
    Patent number: 8420690
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 16, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • Inhibitors of Akt activity
    Patent number: 8338434
    Abstract: Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20110196009
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: October 14, 2009
    Publication date: August 11, 2011
    Inventors: Meagan Rouse, Mark Andrew Seefeld
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20110053972
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 7, 2008
    Publication date: March 3, 2011
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • Antibacterial agents
    Patent number: 7759340
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: July 20, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20100137338
    Abstract: Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: March 28, 2008
    Publication date: June 3, 2010
    Inventor: Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7709472
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: May 4, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7691850
    Abstract: Compounds of formula (I) and derivatives thereof: compositions containing them, their preparation and their use as antibacterials.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: April 6, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Israil Pendrak, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7655648
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7648980
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7648984
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Jeffrey Michael Axten, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7618959
    Abstract: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: November 17, 2009
    Assignee: SmithKlineBeecham Corp
    Inventors: Jeffrey Michael Axten, Timothy Francis Gallagher, William Henry Miller, Mark Andrew Seefeld